Roche: Oddo BHF still a buyer after study on Keytruda
(CercleFinance.com) - Oddo BHF reiterates its "buy" recommendation on Roche, along with its target price of 278 Swiss francs, following the success of the Keynote-189 study which evaluated Keytruda combined with chemotherapy for patients with first-line lung cancer.
Nothing is set in stone at this point, and Roche, along with Merck, seems to have opted for a winning combo strategy (IO + CT) in this indication, said the analyst who monitors the Swiss health group.
He adds that Roche will benefit from a rich newsflow in the first half of 2018, with four studies for Tecentriq and growth sources stemming from Ocrevus (multiple sclerosis), Hemlibra (haemophilia) and Perjeta (extension of indication in breast cancer).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Nothing is set in stone at this point, and Roche, along with Merck, seems to have opted for a winning combo strategy (IO + CT) in this indication, said the analyst who monitors the Swiss health group.
He adds that Roche will benefit from a rich newsflow in the first half of 2018, with four studies for Tecentriq and growth sources stemming from Ocrevus (multiple sclerosis), Hemlibra (haemophilia) and Perjeta (extension of indication in breast cancer).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.